OBJECTIVE: The purpose of this study was to examine the satisfaction of families who participated in the Treatment of Severe Childhood Aggression (TOSCA) study. METHODS:TOSCA was a randomized clinical trial of psychostimulant plus parent training plus placebo (basic treatment) versus psychostimulant plus parent training plus risperidone (augmented treatment) for children with severe physical aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. Parents completed a standardized Parent Satisfaction Questionnaire (PSQ). RESULTS: Of the 168 families randomized, 150 (89.3%) provided consumer satisfaction data. When they were asked if they would join the study again if they had the option to repeat, 136 (91%) said "yes," 11 (7%) said "maybe," and one (<1%) said "no." When asked if they would recommend the study to other parents with children having similar problems, 147 (98%) said "yes" and 3 (2%) said "maybe." Between 71% (rating one aspect of the Parent Training) and 96% (regarding the diagnostic interview) endorsed study procedures using the most positive response option. Asked if there were certain aspects of the study that they especially liked, 64 (43%) spontaneously reported parent training. Treatment assignment (basic vs. augmented) and responder status were not associated with reported satisfaction. However, responder status was strongly associated with parent confidence in managing present (p<0.001) and future (p<0.005) problem behaviors. CONCLUSIONS: These findings indicate high levels of satisfaction with TOSCA study involvement and, taken together with previous pediatric psychopharmacology social validity studies, suggest high levels of support for the research experience. These findings may inform research bioethics and may have implications for deliberations of institutional review boards. TRIAL REGISTRY: Treatment of Severe Childhood Aggression (The TOSCA Study), NCT00796302, clinicaltrials.gov .
RCT Entities:
OBJECTIVE: The purpose of this study was to examine the satisfaction of families who participated in the Treatment of Severe Childhood Aggression (TOSCA) study. METHODS: TOSCA was a randomized clinical trial of psychostimulant plus parent training plus placebo (basic treatment) versus psychostimulant plus parent training plus risperidone (augmented treatment) for children with severe physical aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. Parents completed a standardized Parent Satisfaction Questionnaire (PSQ). RESULTS: Of the 168 families randomized, 150 (89.3%) provided consumer satisfaction data. When they were asked if they would join the study again if they had the option to repeat, 136 (91%) said "yes," 11 (7%) said "maybe," and one (<1%) said "no." When asked if they would recommend the study to other parents with children having similar problems, 147 (98%) said "yes" and 3 (2%) said "maybe." Between 71% (rating one aspect of the Parent Training) and 96% (regarding the diagnostic interview) endorsed study procedures using the most positive response option. Asked if there were certain aspects of the study that they especially liked, 64 (43%) spontaneously reported parent training. Treatment assignment (basic vs. augmented) and responder status were not associated with reported satisfaction. However, responder status was strongly associated with parent confidence in managing present (p<0.001) and future (p<0.005) problem behaviors. CONCLUSIONS: These findings indicate high levels of satisfaction with TOSCA study involvement and, taken together with previous pediatric psychopharmacology social validity studies, suggest high levels of support for the research experience. These findings may inform research bioethics and may have implications for deliberations of institutional review boards. TRIAL REGISTRY: Treatment of Severe Childhood Aggression (The TOSCA Study), NCT00796302, clinicaltrials.gov .
Authors: M L Wolraich; L L Greenhill; W Pelham; J Swanson; T Wilens; D Palumbo; M Atkins; K McBurnett; O Bukstein; G August Journal: Pediatrics Date: 2001-10 Impact factor: 7.124
Authors: Michael G Aman; Oscar G Bukstein; Kenneth D Gadow; L Eugene Arnold; Brooke S G Molina; Nora K McNamara; E Victoria Rundberg-Rivera; Xiaobai Li; Heidi Kipp; Jayne Schneider; Eric M Butter; Jennifer Baker; Joyce Sprafkin; Robert R Rice; Srihari S Bangalore; Cristan A Farmer; Adrienne B Austin; Kristin A Buchan-Page; Nicole V Brown; Elizabeth A Hurt; Sabrina N Grondhuis; Robert L Findling Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-11-18 Impact factor: 8.829
Authors: Cristan A Farmer; L Eugene Arnold; Oscar G Bukstein; Robert L Findling; Kenneth D Gadow; Xiaobai Li; Eric M Butter; Michael G Aman Journal: Child Adolesc Psychiatry Ment Health Date: 2011-11-10 Impact factor: 3.033
Authors: Kenneth D Gadow; Nicole V Brown; L Eugene Arnold; Kristin A Buchan-Page; Oscar G Bukstein; Eric Butter; Cristan A Farmer; Robert L Findling; David J Kolko; Brooke S G Molina; Robert R Rice; Jayne Schneider; Michael G Aman Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-04-13 Impact factor: 8.829
Authors: Jill A Hollway; Michael G Aman; Marissa I Mendoza-Burcham; Laura Silverman; L Eugene Arnold; Rameshwari Tumuluru; Benjamin L Handen; Luc Lecavalier; Kristin Page; Pamela Sayre; Tristram Smith Journal: J Child Adolesc Psychopharmacol Date: 2016-01-21 Impact factor: 2.576
Authors: Heather M Joseph; Cristan Farmer; Heidi Kipp; David Kolko; Michael Aman; James McGinley; L Eugene Arnold; Kenneth D Gadow; Robert L Findling; Brooke S G Molina Journal: J Child Adolesc Psychopharmacol Date: 2018-12-28 Impact factor: 2.576